jRCT2080220535未知3 期
Multi-Centre, Randomised, Double-Blind, Parallel-Group Study to Compare Efficacy and Safety Between Anastrozole (ZD1033) and Tamoxifen in Pre- and Post-Operative Administration Under Luteinising Hormone-Releasing Hormone Agonist Treatment for Premenopausal Breast Cancer Patients
适应症
试验速览
- 阶段
- 3 期
- 发起方
- AstraZeneca
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 干预模型
- Randomized, Double Blind, Active Control, Parallel Assignment Study
入排标准
- 年龄范围
- 20age old over 至 No limit（—）
- 性别
- Female
入选标准
- •Ages Eligible for Study: 20 Years and older
- •Genders Eligible for Study: Female
- •Accepts Healthy Volunteers: No
- •Inclusion Criteria:
- •Premenopausal, estrogen receptor positive women, aged 20 years and over, with operable and measurable breast cancer who have provide written informed consent
- •Exclusion Criteria:
- •Medical history of chemotherapy or endocrine therapy for breast cancer, or with treatment history of radiotherapy. Unwillingness to stop taking any drug known to affect sex hormone status (including hormone replacement therapy (HRT).
排除标准
- 未提供
研究者
相似试验
未知
3 期
Multi-Centre, Randomised, Double-Blind, Parallel-Group Study to Compare Efficacy and Safety Between Anastrozole (ZD1033) and Tamoxifen in Pre- and Post-Operative Administration Under Luteinising Hormone-Releasing Hormone Agonist Treatment for Premenopausal Breast Cancer PatientsBreast CancerJPRN-jRCT2080220535AstraZeneca
进行中（未招募）
1 期
Study to assess the efficacy and safety of MYL-1402O Compared With the drug Avastin, in patients with lung cancer.Stage IV unresectable, recurrent or metastaticnon-squamous non-small cell lung cancer (nsNSCLC)MedDRA version: 20.0Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVSystem Organ Class: 100000004864EUCTR2015-005141-32-HRMylan GmbH640
进行中（未招募）
1 期
Study to assess the efficacy and safety of MYL-1402O Compared With the drug Avastin, in patients with lung cancer.EUCTR2015-005141-32-ITMYLAN GMBH478
进行中（未招募）
1 期
Study to assess the efficacy and safety of MYL-1402O Compared With the drug Avastin, in patients with lung cancer.Stage IV unresectable, recurrent or metastaticnon-squamous non-small cell lung cancer (nsNSCLC)MedDRA version: 19.0Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVSystem Organ Class: 100000004864EUCTR2015-005141-32-HUMylan GmbH478
进行中（未招募）
1 期
Study to assess the efficacy and safety of MYL-1402O Compared With the drug Avastin, in patients with lung cancer.EUCTR2015-005141-32-BGMylan GmbH640